The diversity of T-cell co-stimulation in the induction of antitumor immunity (Q33776121)

29 July 2017

1 reference

title

The diversity of T-cell co-stimulation in the induction of antitumor immunity (English)

1 reference

29 July 2017

Schlom J

1

1 reference

29 July 2017

Hodge JW

series ordinal

2

1 reference

29 July 2017

publication date

1 August 1999

1 reference

29 July 2017

published in

Immunological Reviews

1 reference

29 July 2017

volume

170

1 reference

29 July 2017

page(s)

73-84

1 reference

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Kinetics of formation of neutralizing antibodies against vaccinia virus following re-vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

CD28/B7 costimulation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Structure, expression, and genetic linkage of the mouse BCM1 (OX45 or Blast-1) antigen. Evidence for genetic duplication giving rise to the BCM1 region on mouse chromosome 1 and the CD2/LFA3 region on mouse chromosome 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

The structure and ligand interactions of CD2: implications for T-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Costimulation of T-cell-mediated tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

An alternative pathway of T-cell activation: A functional role for the 50 kd T11 sheep erythrocyte receptor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

Synthetic vaccines for infectious and autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1999.TB01330.X

10.1111/J.1600-065X.1999.TB01330.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference